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ABSTRACT
Mantle cell lymphoma (MCL) and peripheral T cell lymphoma (PTCL) are distinct lymphoma subtypes that each
comprise about10% of the non-Hodgkin lymphomas. Although both subtypes are characterized by high remis-
sion rates to frontline chemotherapy, the prognosis is generally poor because of inevitable relapsewithin 1-2 years
or less, depending on the specific histology. Patients with MCL who achieve a complete remission with upfront
conventional chemotherapy currently have several options for consolidative therapy including maintenance ther-
apywith rituximab, autologoushematopoietic cell transplantation (HCT), andmore recently, allogeneicHCTuti-
lizing a reduced intensity conditioning (RIC) regimen. In the autologous HCT setting, the added efficacy of
rituximab is under active investigation as a method of in vivo purging during hematopoietic cell mobilization, as
part of the conditioning regimen and as post-HCT maintenance therapy. For patients with PTCL, autologous
HCT is commonly offered at relapse but there are a few prospective series utilizing autologous HCT as consoli-
dation ofCR1with encouraging results.There is no conclusive evidence regarding the efficacy of allogeneicHCT,
but outcomeswithRIC regimens appear promising.This review summarizes the current role ofHCT for patients
with MCL in first remission and for patients with PTCL as consolidation and for relapsed/refractory disease.
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Mantle cell lymphoma (MCL) is an aggressiveB cell
lymphoma that is characterized by early dissemination
and an unfavorable clinical course. Because the results
of standard lymphomafirst-line therapy are disappoint-
ing with a median relapse-free survival (RPS) of \2
years even with incorporation of rituximab, a variety
of postremission consolidation strategies is under inves-
tigation [1-3]. Essentially, these are based on 3 elements
proven to be effective in MCL during recent years: an-
tibody maintenance, high-dose ara-C intensification,
and autologous and allogeneic hematopoietic cell trans-
plantation (autoHCT, alloHCT).
Allogeneic HCT and the Role of Rituximab
To improve the dismal prognosis of MCL, mye-
loablative therapy with autoHCT has been extensively100studied since the early nineties. The Nebraska group
was first to show the potential efficacy of this intensive
modality in MCL [4]. Since then, numerous studies
have been published documenting feasibility and po-
tent antilymphoma activity of autoHCT in this entity,
in particular, if used as part of first-line treatment [5-
7]. However, almost all trials were uncontrolled and
suffered from small patient numbers and limited ob-
servation times. Only recently were Dreyling and
coworkers [8] able to demonstrate superiority of au-
toHCT over standard CHOP (cyclophosphamide,
doxorubin, vineristine, prednisone) chemotherapy
with interferon maintenance in terms of progression-
free survival (PFS) in a prospective randomized phase
III study. Nevertheless, with a median follow-up of
34 months, a plateau in the survival curve was not
seen, and a significant survival benefit could not be
shown.
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became evident that this monoclonal antibody (mAb)
was also effective in MCL. The addition of RTX to
standard CHOP chemotherapy yielded promising re-
sponse rates, and resulted in significantly prolonged
times to treatment failure in a prospective randomized
study, although PFS and overall survival (OS) were not
improved [2,9].
Another modality with strong activity in MCL is
represented by intensive ara-C-containing combina-
tion chemotherapy regimens, such as Hyper-CVAD/
Mtx-HA (methotrexate and high-dose ara-C), DHAP,
HAM, and Dexa-BEAM. This conclusion was initially
based on the observation that these regimens used
alone or sequentially after CHOP consistently yielded
response rates of 90% ormore [6,10-12]. A second line
of evidence derives from minimal residual disease
(MRD) studies documenting a median reduction of
the tumor load of more than 1 log with Dexa-BEAM,
whereas CHOP-like regimens had no significant
impact on MRD [13].
Further improvement of first-line treatment results
could be achieved by combinations of these 3 MCL-ac-
tive modalities (rituximab, HA, and autoHCT). The
M.D. Anderson group examined the combination of
RTX with repetitive hyper-CVAD/Mtx-HA as first-
line treatment of MCL in a large prospective phase II
trial. With an 87% complete remission (CR) rate, fail-
ure-free survival (FFS) after 3 years was 64%, and thus
comparable to results achieved with sequential HA-au-
toHCT. However, because the toxicity of this regimen
was substantial, with 5% toxic deaths and a number of
secondary t-MDS, it does not appear to have significant
advantagesover autoHCT[14].Twosmall studies inves-
tigated the combination of autoHCTwithRTXmainte-
nance as part of first-line treatment not including HA
[15,16]. Disease control was very promising, although
the results must be regarded as preliminary because of
low patient numbers and short observation times.
More experience has been gained with the triple combi-
nation rituximab-HA-autoHCT using RTX mainly
pre-HCT for in vivo purging. Although follow-up was
limited, PFS appeared to be consistently higher than
60% after 3 years [10,17,18]. The Nordic lymphoma
group reported the results of 2 subsequent prospective
phase II trials with first-line treatment of MCL [19].
Forty-twopatientswere enteredon aprotocol consisting
of 3 cycles of intensified CHOP. Responders were con-
solidated with BEAM followed by autoHCT. With an
overall response rate of 74% toCHOP,FFS after 3 years
was 24%. Subsequently, the regimen was intensified by
addition of 2 rounds of HA after CHOP and 2 doses of
RTX for in vivo purging prior to hematopoietic stem
cell collection. By the time of reporting, 130 evaluable
patients were enrolled on the second protocol. Overall
response to CHOP-rituximab-BEAM was 91%, trans-
lating to a 3-year FFS of 67%, which was significantlysuperior to the first protocol. Meanwhile, this trial has
been completed with preliminary results confirming
a plateau in FFS survival above 60% (C. Geisler, per-
sonal communication, September 2007).
To date, however, the most compelling evidence
for a beneficial effect of adding RTX to the HA-au-
toHCT sequence is provided by a study analyzing
the effect of 2 doses of peritransplant RTX in first-
line autoHCT in MCL. In a prospective phase II de-
sign, patients with newly diagnosedMCL were treated
with a sequential dose-escalating therapy comprising
standard chemotherapy for remission induction, in-
tensive ara-C-containing chemotherapy for mobiliza-
tion of hematopoietic stem cells, and myeloablative
therapy followed by autoHCT. The myeloablative
regimen consisted of total body irradiation (TBI)
and high-dose cyclophosphamide supplemented with
2 doses (375 mg/m2) of RTX. Outcome parameters
(toxicity, clinical, and molecular response as assessed
by allele-specific IGH real-time PCR, event-free sur-
vival (EFS), and OS were compared with those of 34
historic controls treated identically but without
RTX. Thirty-four patients were accrued. Results
were initially analyzed as of April 2006, and updated
for the purpose of this Education Supplement with
a median follow-up of 38 (6-104) months for the
RTX group and 90 (4-174) months for the controls
[20]. EFS was significantly increased with peritrans-
plant RTX (Figure 1). This was associated with a trend
for a superior molecular response rate in 11 study pa-
tients versus 10 control patients with an available
marker (73% versus 30%, P 5 .086). In a subsequent
study, we showed that results could be further im-
proved by RTX maintenance therapy instead of peri-
transplant RTX (Rieger et al., unpublished). This
was consistent with the favorable outcome observed
in the previously mentioned 2 phase II studies includ-
ing short-term RTX maintenance [15,16]. An advan-
tage of posttransplant RTX is also suggested by
results from the Nordic Lymphoma Group trials indi-
cating that MRD recurrence after autoHCT can be
ameliorated by preemptive infusion of RTX [19].
Allogeneic HCT
Another potentially curative option is consolida-
tion with alloHCT after having achieved response
with effective primary therapy including autoHCT
[21]. The rationale of alloHCT stems from the possi-
bility of superior antilymphoma efficacy because of the
graft-versus-lymphoma effect associated with al-
loHCT. Compared to autoHCT, relapse rates appear
to be lower after alloHCT, but this has not translated
into a superior OS because of significant nonrelapse
mortality (NRM) even with reduced-intensity condi-
tioning (RIC). Considering the good outcome data
with antibody-/autoHCT-based consolidation, the
102 P. Dreger and G. G. Laportadvanced age of the patients, the toxicity of alloHCT,
and the paucity of data in favor of first-line alloHCT
(Table 1), this procedure cannot be regarded as evi-
dence-based treatment for MCL in first CR, and
should be only performed within clinical trials. A strat-
egy of reserving alloHCT for second-line therapy is
further supported by the fact that, in contrast to au-
toHCT, alloHCT can also yield favorable results in
the salvage setting [22,23].
FUTURE DIRECTIONS
Beyond these established modalities, more recent
innovations with documented activity in MCL, such
as radioimmunotherapy, proteasome inhibitors,
mTOR inhibitors, and ‘‘small molecules,’’ promise to
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Figure 1. Updated EFS following autoSCT after myeloablative
therapy with (broken line, n 5 34) or without peritransplant rituxi-
mab (solid line, n 5 34).further enhance the efficacy of therapy. With regard
to radioimmunotherapy, both Y90 ibritumomab tiuxe-
tan and and I131 tositumomab have been shown to be
safe and effective when used together with high-dose
etoposide and cyclophosphamide for myeloablation
prior to autoHCT in relapsed or refractory MCL
[24,25]. The German Lymphoma Study Group is cur-
rently performing a phase II trial withY90 ibritumomab
tiuxetan/high-dose cyclophosphamide myeloablation
followed by autoHCT in relapsed MCL. More re-
cently, the therapeutic efficacy of the proteasome in-
hibitor, bortezomib, in MCL has been investigated.
Whereas single-agent bortezomib appears to be clearly
inferior to accepted standard regimens when used as
first-line treatment, it may have a place in the salvage
setting or in combinationwith otherMCL-active com-
pounds [26-28]. Other novel drugs with potential
efficacy in MCL are temsirolimus, everolimus or BCL-
2 inhibitors [29-31]. However, none of these agents
alone or in combination has an established place in
first-line treatment of MCL to date.
Taken together, withmodern treatment approaches
including autoHCT and rituximab, the prognosis of
MCL at least in younger patients today has dramati-
cally improved compared to the old days of CHOP
monotherapy. Continuing innovation in this field
makes cure of this disease even without allogeneic
HCT a realistic goal.
PERIPHERAL T CELL LYMPHOMAS: INTRODUCTION
The peripheral T cell lymphoma (PTCL) repre-
sent a heterogeneous group of lymphomas and account
for approximately 10% to 15% of the non-HodgkinsTable 1. Allogeneic SCT for Mantle Cell Lymphoma
Study Design n
CR1
(%)
MSD
(%)
TCD
(%)
Conditioning
(n)
Follow-up
(months) 2-y NRM 2-y DFS 2-y OS
Khouri et al. [21] phase II; 16 31% 94% 0 TBI/Cy (11) 6 of 16 55% (3 y) 55% (3 y)
BEAM (3)
Fu/araC/cisplatin (2)
Laudi et al. [52] phase II 17 29% 79% 0 TBI/Cy (10) 31 29% 50% 49%
Fu/Bu/TBI (3)
Fu/Cy/TBI (4)
Ganti et al. [53] retrospective 17 n.a. 100% 0 TBI/Cy (15) 33 19% (3 mo) 53% 58%
TBI/Cy (1)
Bu/Cy (1)
Reduced intensity
conditioning
Maris et al. [22] phase II; 33 0 48% 0 TBI2/F 25 24% 60% 65%
Robinson et al. [54] registry 22 n.a. n.a. n.a. RIC miscellaneous 9 82% 0 18%
Khouri et al. [23] phase II 18 0 72% 0 FC-R (13) 26 2 of 18 82%* 86% (3 y)
Fu/araC/cisplatin (5)
Morris et al. [55] phase II 10 n.a. n.a. 100% Fu/Mel/CD52 36 20% 50% (3 y) 60% (3 y)
BEAM indicates carmustine, etoposide, ara-C, high-dose melphalan; Bu, busulfan; CD52, alemtuzumab; CR1, first complete remission; Cy,
high-dose cyclophosphamide; DFS, disease-free survival; Fu, fludarabine; FC-R, fludarabine, cyclophosphamide, rituximab; Mel, high-
dose melphalan; RIC, reduced-intensity conditioning; TBI/Cy, total body irradiation, high-dose cyclophosphamide; TBI2, low-dose
TBI; NRM, nonrelapse mortality; OS, overall survival; MSD, matched sibling donor; TCD, T cell depletion; y, years; mo, months.
*Current progression-free survival.
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classification, there are 9 distinct clinicopathologic
subtypeswith distinct characteristics and varied clinical
courses. The most common subtypes are PTCL-un-
specified (PTCL-u) and anaplastic large cell lymphoma
(ALCL), which comprise approximately 50% and 25%
of all PTCLhistologies, respectively. Compared to the
B cell lymphomas, PTCL tends to present in extrano-
dal sites and generally carry a poorer prognosis with
5-year survival of\30% [32]. One exception, however,
are patients with anaplastic lymphoma kinase (ALK)-
positive anaplastic ALCLwhere 5-year survival reaches
60% to 90% after conventional therapy [33]. Despite
less than optimal results, frontline chemotherapy with
CHOPorCHOP-like regimens remain themost com-
monly used regimens with more intensive regimens
such as hyperCVAD unable to significantly improve
upon these results [34].
Regarding the role of HCT, it is difficult to draw
definitive conclusions about the efficacy of HCT in
this patient population because of the low incidence
of this disease and the heterogeneity of the subtypes.
Numerous reports detailing HCT for PTCL have
been published, but most series are of small sample
sizes with various histologies. The utility of alloHCT
is less definitive, as there are very few reports specifi-
cally utilizing this modality and most alloHCT cases
are intermingled with autoHCT reports. The follow-
ing report summarizes published experience with au-
toHCT and alloHCT for patients with PTCL.
Autologous HCT
High-dose chemotherapy with autoHCT for re-
lapsed/refractory aggressive B cell lymphomas offers
the best chance for long-term survival in patients
with chemosensitive disease. However, its efficacy for
patients with relapsed/refractory PTCL is less clearly
defined, as no prospective HCT trial has been
conducted and patients with PTCL comprise a smallproportion in most HCT reports for aggressive
NHL. Given the poor prognosis of most PTCL sub-
types, autoHCT has been offered as consolidation of
first remission (CR1) and for patients with relapsed
and refractory disease.
RELAPSED/REFRACTORY DISEASE
The majority of published case series describes the
results of autologous HCT in the relapsed/refractory
setting with PTCL-u and ALCL being the predomi-
nant subtypes in these trials (see Table 2). Several
pre-HCT factors identified that aid in predicting
outcome after autoHCT include chemosensitivity,
pretransplant International Prognostic Index (IPI)
(score, pretransplant lactate dehydrogenase [LDH]),
disease status, beta-2-microglobulin and histology
[35-38]. One of the largest series published to date
comes from the Spanish GEL-TAMO (Grupo Espa-
nol de Linfomas/Transplante Autologo de Medula
Osea) group [36]. This was a heterogeneous group of
115 patients in which approximately 32% of patients
were in CR1 at the time of HCT with the rest of the
patients being beyond CR1 or with refractory disease.
With a median follow-up of 37 months, the 5-year OS
and disease-free survival (DFS) for all patients was
56% and 60%, respectively. For the patients trans-
planted in CR1, the OS and DFS at 5 years were both
80%, in contrast to the 6 patients with refractory dis-
ease, who had anOS of 0%. Pre-HCT factors that cor-
relatedwith outcomewereLDH, age-adjusted IPI, and
disease status. A recent retrospective study from the
BSBMT (British Society of Bone Marrow Transplant)
and the ABMTRR (Australian Bone Marrow Trans-
plant Recipient Registry) of 64 patients with PTCL
also identified chemosensitivity as the most important
predictor for both PFS andOS bymultivariate analysis
[37]. The 3-year PFS and OS were 50% and 53%, res-
pectively, with a median OS of 52 months. Patients
with chemosensitive disease had a 3-year OS of 58%Table 2. Autologous Hematopoietic Cell Tranplantation for Relapsed/Refractory Peripheral T Cell Lymphoma
Group/Year n Median Age (Range) Preparative Regimen DFS/PFS OS Follow-up Relapse TRM
BSMT/ABMTRR [37] 2007 64 51 y (17-70) varied 50 53 37 mo 32 9
Cleveland Clinic [43] 2007 32 44 (16-69) Bu/VP16/Cy 18 34 30 mo 69 NR
South Korea [56] 2007* 40 44 (18-68) BEAM,BEAC others 25 46 16 mo 58 NR
MSKCC [38] 2006 24 48 (24-73) varied 24 33 72 mo 83 NR
Vanderbilt [42] 2004* 28 39 (8-60) TBI/Cy/VP16, 50 69 3y 32 NR
GEL-TAMO [36] 2003* 115 41 (13-72) BEAM,BEAC 51 56 37 mo NR 8
Princess Margaret [57] 2003 36 46 (19-62) Mel/VP16,TBI/VP/Mel 37 48 42mo NR 17
Sweden [40] 2001 40 42 (16-61) BEAM, BEAC others 48 58 25mo NR 8
BSMBT indicates British Society of Bone Marrow Transplantation; ABMTRR, Australian Bone Marrow Transplant Recipient Registry;
MSKCC, Memorial Sloan Kettering Cancer Center; GEL-TAMO, Grupo Espanol de Linfomas/Transplante Autologo de Medula Osea;
bu, busulfan; Cy, cyclophosphamide; Mel, melphalan; DFS/PFS, disease-free survival/progression-free survival; OS, overall survival; mo,
months; y, years; UK, United Kingdom; TBI, total body irradiation; BEAC, carmustine, etoposide, cytarabine, cyclophosphamide;
BEAM, carmustine, etoposide, cytarabine, melphalan; TRM, treatment-related mortality; NR, not reported.
*Includes first remission patients.
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Group/Year n Median Age (Range) Preparative Regimen DFS/PFS OS Follow-up TRM
GEL-TAMO [58] 2003 74 46 (15-69) BEAM,BEAC Cy/TBI, CBV 63 68 67mo 4
Italy [48] 2006 62 43 (20-60) Mitoxantrone/Mel,BEAM 30 34 76mo 5
GELA [59] 2004 52 39 (16-60) CBV, BEAM NR 44 6.5y NR
Germany [47] 2004 30 46 (30-62) TBI/Cy Not reached Not reached 15mo 3
GEL-TAMO indicates Grupo Espanol de Linfomas/Transplante Autologo de Medula Osea; GELA, Groupe d’Etude des Lymphomas de
l’Adulte; Cy, cyclophosphamide; DFS/PFS, disease-free survival/progression-free survival; OS, overall survival; BEAC, carmustine, etopo-
side, cytarabine, cyclophosphamide; BEAM, carmustine, etoposide, cytarabine, melphalan; Mel, melphalan; TBI, total body irradiation;
TRM, treatment-related mortality; CBV, cyclophosphamide, carmustine, VP16. mo, months; y, years.versus 36% for patients with chemorefractory disease
(P5 .007).
The age-adjusted IPI at the time of relapse, also
known as the second line age-adjusted IPI (sAA-IPI),
has been identified as an important prognostic factor
prior to HCT. Investigators from Memorial Sloan
Kettering reported the outcomes of 24 PTCL patients
with relapsed or primary refractory disease but ex-
cluded patients with ALK-positive ALCL [38]. With
a median follow-up of 6 years, the 5-year PFS and
OS were 24% and 33%, respectively, with disease pro-
gression occurring in 83% of patients. The sAA-IPI
was the only variable significant for both PFS and
OS in multivariate analysis. Interestingly, when these
outcomes were compared to 86 consecutive patients
with chemosensitive relapsed or primary refractory
diffuse large B cell lymphomas, there was no signifi-
cant difference with respect to disease progression or
survival after progression when stratified by the sAA-
IPI. This finding suggests that autoHCT may over-
come the adverse prognosis associated with T cell
histology in the relapsed setting. The GEL-TAMO
group also found that sAA-IPI correlated with survival
among PTCL patients who achieved less than a CR af-
ter induction chemotherapy [39]. However, IPI at the
time of initial diagnosis does not appear to impact out-
come after autoHCT [40,41].
Among the PTCL subtypes, the impact of histo-
logic subtype on outcome after HCT is less defined
with the exception of patients with ALK1 ALCL
who typically have superior survivals compared to
those with non-ALCL histologies. ALCL patients
comprise a subgroup of PTCL with higher CR rates
and improved OS, and thus, the role of autoHCT is
more appropriate in the relapsed setting. In a series
of 28 relapsed PTCL patients from Vanderbilt Uni-
versity, investigators aimed to determine if histology
impacted the outcomes of 28 relapsed PTCL patients
after autoHCT [42]. The 3-year EFS and OS were
69% and 50%, respectively, but when ALCL patients
were analyzed separately, the 3-yearOSwas 86% com-
pared to 47% for the non-ALCL patients (P 5 .01).
The ALK-positive ALCL patients fared best, with an
EFS of 100% versus 0% compared to ALK-negativeALCL. Furthermore, in a Norwegian study of 40 pa-
tients with PTCL, the subgroup of 14 patients with
ALCL also showed a trend for better OS compared
to the other PTCL histologies, 79% versus 44%, P
5 .08 [40]. Another recent report of 32 PTCL patients
did not demonstrate a survival advantage for the
ALCL patients, although the ALK status was known
only in about half of the 21 ALCL patients [43].
Thus, most published results so far indicate that
a high proportion of relapsed ALK1 ALCL patients
are cured with autoHCT.
A few reports from Europe have described the re-
sults of autoHCT specifically for angioimmunoblastic
T cell lymphoma (AITL), a rare and aggressive sub-
type that usually affects older patients and is character-
ized by systemic disease with lymphadenopathy, fever,
weight loss, ascites, and polyclonal gammopathy.
Prognosis is poor, with a long-term survival rate of
10% to 30% and a median survival of\3 years [44].
The Spanish GEL-TAMOgroup described the results
with autoHCT in 19 AITL patients, most of whom
were in CR1 and reported a 3-year PFS and OS of
55% and 60% [45]. A similar report from an EBMT
retrospective analysis in 29 AITL patients showed
a 5-year EFS and OS of 37% and 44%, with nearly
half of the patients in CR1 at the time of HCT [46].
The achievement of CR after HCT was a favorable
prognostic factor, as those patients experienced an
OS of 62%. Thus, autoHCTmay improve the survival
of AITL patients, especially if offered HCT in CR1.
FIRST REMISSION
Given the poor outcomes after conventional che-
motherapy, the role of HCT as consolidation therapy
in CR1 has been explored. Four published reports to
date (see Table 3) demonstrate the feasibility of au-
toHCT as consolidation therapy. The first prospective
PTCL-restricted multicenter study incorporating au-
toHCT as part of first-line therapy accrued 30 patients
with various PTCL histologies [47]. Patients received
4-6 cycles of CHOP followed by further induction
chemotherapy prior to autoHCT with a preparative
regimen of TBI and cyclophosphamide. Twenty-one
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rate after HCT. With a 15-month median follow-up,
76%of theHCTpatients remained in CR. Progressive
disease was themain obstacle in proceeding toHCT. A
report from Italy of 68 PTCL patients with a lengthy
follow-up of over 6 years combined the results of 2
prospective phase 2 trials investigating the role of
high-dose sequential chemotherapy followed by autol-
ogous HCT in 62 patients with advanced stage PTCL
[48]. The 12-year EFS and OS was a disappointing
30% and 34%, respectively, for all patients. However,
the subset of ALK positive patients fared better with
a 12-year OS of 62%. Multivariate analysis showed
that achievement of CR prior to HCT was a statisti-
cally significant factor in terms of EFS and OS (P\
.0001), indicating the importance of chemosensitivity.
This was an intent-to-treat analysis, and it should be
mentioned that 26% of patients did not proceed to
HCT because of progressive disease as in the previ-
ously mentioned German study. The Spanish GEL-
TAMO group published a large retrospective series
of 75 PTCL patients using autoHCT as consolidation
in CR1 [49]. The PTCL-u histology comprised 50%
of patients with ALCL patients being the second
most frequent histology (30%). The 5-year PFS and
OS was an encouraging 63% and 68%, respectively,
for all patients. When the outcomes of the ALCL pa-
tients were compared to the non-ALCL histologies,
the PFS and OS were significantly superior (80% ver-
sus 55%, P 5 .03 and 84% versus 61%, P 5 .058, re-
spectively) despite the fact that the ALK status was
not available in most of the ALCL patients. In sum-
mary, autoHCT as a frontline therapy is a reasonable
option for PTCL patients considering their inherently
poor prognosis. Current data shows that this modality
may increase the OS of such patients compared to con-
ventional therapy. However, for ALK1 ALCL pa-
tients who carry a more favorable prognosis, HCT
should be reserved in the event of relapse or for induc-
tion failures.
Allogeneic HCT
The experience with alloHCT for PTCL is limited
to only a few published studies with small numbers of
patients. One of the larger series comes from the
BSBMT and ABMTRR group in which 18 patients
underwent myeloablative allogeneic HCT [37]. Nine
patients had PTCL-u, with the rest having ALCL, T
cell leukemia, and cutaneous T cell lymphoma. Thir-
teen (72%) patients received grafts from matched-re-
lated donors. With a median follow-up of nearly 6
years, the PFS andOSwas 33% and 39%, respectively,
with a 3-year relapse rate of 39%. Although themedian
age of this group was only 28 years old (range: 2-52
years old), the TRM of 38% was significant. In a Japa-
nese report of 28 patients, 23 patients underwent mye-loablative conditioning with 5 patients receiving
a reduced intensity regimen. The 2-year PFS and OS
of 34% and 40%, respectively, but the TRM was
30% for the myeloablative recipients and 20% for
the RIC recipients [50]. RIC regimens, however, may
show more promise with less toxicity [51]. An Italian
group conducted a prospective phase II trial utilizing
a RIC regimen with fludarabine (Flu), thiotepa, and
cyclophosphamide in 17 patients with refractory or re-
lapsed disease. This regimen was well tolerated, with
an NRM of 6% at 2 years. The 3-year PFS and OS
was an encouraging 64% and 81%, respectively.
Four patients received DLI, with responses seen in 2
patients suggesting the existence of a graft-versus-lym-
phoma effect.
SUMMARY
HCT is being increasingly offered to patients with
MCL and PTCL as consolidation in CR and for re-
lapsed disease. For MCL patients in CR1, the efficacy
of autoHCT appears to be improved especially when
RTX is incorporated in the peritransplant period. Ev-
idence exists for a graft-versus-lymphoma effect in
MCL and early results with allogeneic RIC regimen
appear encouraging, although NRM incidence is vari-
able among published series. The role of autoHCT as
part of induction therapy in PTCL is still under de-
bate, but given the inherently poor prognoses of
most T cell histologies, it is reasonable to offer HCT
early in their treatment course. Patients with a high-
risk IPI at the time of diagnosis should be considered
for autoHCT or perhaps RIC alloHCT as consolida-
tion of CRI. AutoHCT for relapsed PTCL appears
to benefit those with chemosensitive disease, especially
patients with ALK1 ALCL. For both MCL and
PTCL, only large prospective studies in the multicen-
ter setting with lengthy follow-up will have the ability
to truly measure the impact of HCT in these aggres-
sive disease entities.
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